New MRI scan could spare NASH patients painful liver biopsies

NCT ID NCT04054310

Recruiting now Diagnosis Sponsor: Perspectum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new, non-invasive MRI scan (called cT1) to see if it can accurately diagnose NASH, a serious liver disease. Currently, doctors need to take a small sample of liver tissue with a needle (biopsy) to confirm the diagnosis. The study will compare the MRI results with biopsy results in 225 adults who are already scheduled for a biopsy. If the scan works well, it could replace the need for many painful biopsies in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH - NONALCOHOLIC STEATOHEPATITIS

Contacts and locations

Locations

Arizona Liver Health
RECRUITING

Chandler, Arizona, 85224, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Indiana University Health
RECRUITING

Indianapolis, Indiana, 46202, United States
Liver Center of Texas
ACTIVE_NOT_RECRUITING

Dallas, Texas, 75234, United States
RUSH University Medical Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22908, United States
Virginia Common wealth University
RECRUITING

Richmond, Virginia, 23284, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.